Preferred Label : receptors, vascular endothelial growth factor;

MeSH definition : A family of closely related RECEPTOR PROTEIN-TYROSINE KINASES that bind vascular endothelial growth factors. They share a cluster of seven extracellular Ig-like domains which are important for ligand binding. They are highly expressed in vascular endothelial cells and are critical for the physiological and pathological growth, development and maintenance of blood and lymphatic vessels.;

MeSH synonym : receptor, vascular endothelial cell growth factor; receptor, vascular permeability factor; receptors, vegf; vascular endothelial cell growth factor receptor; vascular endothelial growth factor receptor; vascular permeability factor receptor; vegf receptor; vegf receptors; vpf receptor;

CISMeF synonym : EC 2.7.1.112;

MeSH Hyperonym : endothelial growth factor receptor; Receptor, Endothelial Growth Factors;

Registry Number MeSH : EC 2.7.10.1;

MeSH annotation : GEN; prefer specifics, DF: VEGF RECEPT; general; prefer specifics;

Wikipedia link : https://en.wikipedia.org/wiki/Receptors, vascular endothelial growth factor;

Is substance : O;

UNII : EC 2.7.10.1;

Details


Main resources

You can consult :

A family of closely related RECEPTOR PROTEIN-TYROSINE KINASES that bind vascular endothelial growth factors. They share a cluster of seven extracellular Ig-like domains which are important for ligand binding. They are highly expressed in vascular endothelial cells and are critical for the physiological and pathological growth, development and maintenance of blood and lymphatic vessels.

https://ansm.sante.fr/tableau-marr/aflibercept
2023
false
false
false
France
French
guidelines for drug use
patients guideline
aflibercept
recombinant fusion proteins
receptors, vascular endothelial growth factor
Drug-Related side effects and adverse reactions
signs and symptoms
intravitreal injections

---
https://ansm.sante.fr/informations-de-securite/eylea-40-mg-ml-aflibercept-en-injection-intravitreenne-risque-plus-eleve-daugmentation-de-la-pression-intraoculaire-a-la-suite-de-lutilisation-de-la-seringue-preremplie
2021
false
false
false
France
French
pharmacovigilance note
intravitreal injections
aflibercept
ocular hypertension
aflibercept
Pre-filled Syringe
drug compounding
intravitreal injections
aflibercept
guidelines for drug use
continuity of patient care
Inappropriate preparation of medication
recombinant fusion proteins
receptors, vascular endothelial growth factor
recombinant fusion proteins
receptors, vascular endothelial growth factor

---
https://www.e-cancer.fr/Expertises-et-publications/Catalogue-des-publications/Medicaments-ciblant-VEGFR-axitinib-cabozantinib-pazopanib-sorafenib-sunitinib
2019
false
false
false
France
Axitinib
cabozantinib
pazopanib
Sorafenib
Sunitinib
Drug-Related side effects and adverse reactions
Drug-Related side effects and adverse reactions
risk factors
patient education as topic
continuity of patient care
administration, oral
receptors, vascular endothelial growth factor
carcinoma, renal cell
drug interactions
pregnancy
Tyrosine Kinase Inhibitors
guidelines for drug use
Sorafenib
pazopanib
Axitinib
Sunitinib
cabozantinib
pyrimidines
sulfonamides
anilides
pyridines
pyrimidines
sulfonamides
anilides
pyridines
anilides
pyridines
pyrimidines
sulfonamides

---
Summary Safety Review - Vascular endothelial growth factor receptor tyrosine kinase inhibitors
https://hpr-rps.hres.ca/reg-content/resume-examen-innocuite-detail.php?lang=fr&linkID=SSR00213
2018
false
false
false
Canada
French
English
receptors, vascular endothelial growth factor
protein kinase inhibitors
soft tissue neoplasms
kidney neoplasms
liver neoplasms
arteries
aneurysm
Aortic Dissection
aorta
pazopanib
ponatinib
regorafenib
vandetanib
lenvatinib
administration, oral
risk assessment
pharmacovigilance note
Tyrosine Kinase Inhibitors
indoles
pyrroles
phenylurea compounds
niacinamide
niacinamide
imidazoles
indazoles
pyrimidines
sulfonamides
pyridazines
pyridines
piperidines
quinazolines
quinolines
Sorafenib
Sunitinib
Axitinib

---
https://pharmacomedicale.org/medicaments/par-specialites/item/medicaments-de-la-dmla
2018
false
true
false
France
intravitreal injections
Ranibizumab
Bevacizumab
aflibercept
receptors, vascular endothelial growth factor
vascular endothelial growth factors
angiogenesis inhibitors
Tyrosine Kinase Inhibitors
drug information
wet macular degeneration
recombinant fusion proteins
receptors, vascular endothelial growth factor

---
https://www.has-sante.fr/portail/jcms/c_2800955/fr/place-dans-la-strategie-therapeutique-de-lucentis-eylea-et-de-leurs-comparateurs-cliniquement-pertinents-dans-la-forme-neovasculaire-humide-de-la-dmla
2017
false
false
false
France
French
evaluation of the transparency committee
intravitreal injections
wet macular degeneration
comparative effectiveness research
vascular endothelial growth factor a
Ranibizumab
ranibizumab
treatment outcome
aflibercept
aflibercept
Bevacizumab
angiogenesis inhibitors
risk management
receptors, vascular endothelial growth factor
recombinant fusion proteins

---
http://www.has-sante.fr/portail/jcms/c_2589764/fr/eylea
2016
false
France
French
macular edema
retinal vein occlusion
aflibercept
insurance, health, reimbursement
intravitreal injections
adult
aflibercept
vascular endothelial growth factor a
treatment outcome
visual acuity
evaluation of the transparency committee
receptors, vascular endothelial growth factor
recombinant fusion proteins

---
http://www.has-sante.fr/portail/jcms/c_2671791/fr/eylea
http://www.has-sante.fr/portail/jcms/c_2671791/fr/eylea-aflibercept-anti-vegf
2016
false
false
false
France
French
evaluation of the transparency committee
guidelines for drug use
adult
treatment outcome
aflibercept
aflibercept
aflibercept
intravitreal injections
choroidal neovascularization
myopia
visual acuity
vision disorders
insurance, health, reimbursement
vascular endothelial growth factors
recombinant fusion proteins
receptors, vascular endothelial growth factor
recombinant fusion proteins
receptors, vascular endothelial growth factor

---
http://www.has-sante.fr/portail/jcms/c_2025589/fr/eylea
http://www.has-sante.fr/portail/jcms/c_2025589/fr/eylea-aflibercept-anti-vegf
2015
false
France
French
macular edema
guidelines for drug use
diabetic retinopathy
diabetes complications
aflibercept
aflibercept
insurance, health, reimbursement
intravitreal injections
adult
aflibercept
vascular endothelial growth factor a
treatment outcome
visual acuity
evaluation of the transparency committee
receptors, vascular endothelial growth factor
receptors, vascular endothelial growth factor
recombinant fusion proteins
recombinant fusion proteins

---
http://www.has-sante.fr/portail/jcms/c_1751177/fr/eylea
2014
false
France
French
macular edema
retinal vein occlusion
guidelines for drug use
aflibercept
aflibercept
insurance, health, reimbursement
intravitreal injections
adult
aflibercept
vascular endothelial growth factor a
treatment outcome
randomized controlled trials as topic
visual acuity
evaluation of the transparency committee
receptors, vascular endothelial growth factor
receptors, vascular endothelial growth factor
recombinant fusion proteins
recombinant fusion proteins

---
http://base-donnees-publique.medicaments.gouv.fr/extrait.php?specid=60089217
2014
false
false
false
France
French
package leaflet
summary of product characteristics
aflibercept
perfusion
perfusion, nos
solution, nos
aflibercept
solutions
perfusion
solutions
recombinant fusion proteins
receptors, vascular endothelial growth factor

---
http://www.has-sante.fr/portail/jcms/c_1554433/fr/eylea
2013
false
France
French
guidelines for drug use
aflibercept
aflibercept
insurance, health, reimbursement
intravitreal injections
adult
wet macular degeneration
aflibercept
vascular endothelial growth factor a
Placenta Growth Factor
treatment outcome
randomized controlled trials as topic
visual acuity
evaluation of the transparency committee
receptors, vascular endothelial growth factor
receptors, vascular endothelial growth factor
recombinant fusion proteins
recombinant fusion proteins
pregnancy proteins
comparative study

---
http://www.meddispar.fr/Medicaments/EYLEA-40-B-1/(type)/letter/(value)/E/(cip)/3400926783679
2013
France
French
drug information
aflibercept
aflibercept
drug prescriptions
legislation, drug
intravitreal injections
wet macular degeneration
receptors, vascular endothelial growth factor
recombinant fusion proteins

---
https://www.ema.europa.eu/medicines/human/EPAR/Eylea
2012
false
United Kingdom
English
French
aflibercept
drug approval
europe
treatment outcome
aflibercept
adult
wet macular degeneration
summary of product characteristics
package leaflet
drug evaluation
syndication feed
vascular endothelial growth factor a
Placenta Growth Factor
intravitreal injections
recombinant fusion proteins
recombinant fusion proteins
pregnancy
breast feeding
fertility
randomized controlled trials as topic
drug evaluation, preclinical
pregnancy proteins
receptors, vascular endothelial growth factor
receptors, vascular endothelial growth factor
comparative study
aflibercept

---
https://www.jle.com/fr/revues/medecine/bdc/e-docs/00/04/45/B9/resume.phtml?type=text.html
2009
France
French
journal article
molecular targeted therapy
thyroid neoplasms
receptors, vascular endothelial growth factor

---
https://www.jle.com/fr/revues/medecine/bdc/e-docs/00/04/4A/6A/resume.phtml?type=text.html
2009
France
French
journal article
Tyrosine Kinase Inhibitors
carcinoma, hepatocellular
epidermal growth factor
receptors, vascular endothelial growth factor
vascular endothelial growth factor a
carcinoma, hepatocellular
antibodies, monoclonal
ErbB Receptors

---
https://www.jle.com/fr/revues/medecine/bdc/e-docs/00/04/47/0A/resume.phtml
2009
France
French
journal article
Tyrosine Kinase Inhibitors
angiogenesis inhibitors
lung neoplasms
otorhinolaryngologic neoplasms
receptors, vascular endothelial growth factor
vascular endothelial growth factor a
antibodies, monoclonal

---
Nous contacter.
15/05/2024


[Home] [Top]

© Rouen University Hospital. Any partial or total use of this material must mention the source.